FrancophonIA/ELRC3.0 huggingface dataset:
English: The most serious side effects are gastrointestinal perforation (hole in the gut wall), haemorrhage (bleeding) and arterial thromboembolism (blood clots in the arteries).
Estonian: Kõige raskemad kõrvalnähud on seedekulgla perforatsioon (sooleseina mulgustus), verejooksud ja arterite trombemboolia (trombid ehk soonesisesed verehüübed arterites).
English: Mvasi must not be used in people who are hypersensitive (allergic) to bevacizumab or any of the other ingredients, to Chinese hamster ovary cell products or other recombinant antibodies.
Estonian: Mvasit ei tohi kasutada patsiendid, kes võivad olla bevatsisumaabi või selle ravimi mis tahes muu koostisaine, samuti hiina hamstri munasarjarakkude saaduste või muude rekombinantsete antikehade suhtes ülitundlikud (allergilised).
English: For the full list of all side effects reported with Mvasi, see the package leaflet.
Estonian: Mvasi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: • a type of lung cancer called non-small cell lung cancer when it is advanced or has spread or come back, and cannot be treated with surgery, including cases where the cancer cells have a mutation
Estonian: • Mitteväikerakk-kopsuvähk, kui see on kaugelearenenud, levinud või taastunud ja seda ei saa ravida kirurgiliselt, sealhulgas juhtudel, kus vähirakkudes on mutatsioon (muutus) EGFR-valku tekitavas geenis.
English: How does Mvasi work?
Estonian: Kuidas Mvasi toimib?
English: What benefits of Mvasi have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Mvasi kasulikkus?
English: The doctor may decide to interrupt or stop treatment if the patient develops certain side effects.
Estonian: Kui patsiendil tekivad teatud kõrvalnähud, võib arst ravi katkestada või peatada.
English: How is Mvasi used?
Estonian: Kuidas Mvasit kasutatakse?
English: The active substance in Mvasi, bevacizumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to vascular endothelial growth factor (VEGF), a protein that circulates in the blood and makes blood vessels grow.
Estonian: Mvasi toimeaine bevatsisumaab on monoklonaalne antikeha (teatud valk), mis tunneb ära veres sisalduva ja veresoonte kasvu soodustava valgu vaskulaarse endoteeli kasvuteguri (VEGF) ja seondub sellega.
English: The Agency recommended that Mvasi be given marketing authorisation.
Estonian: Amet soovitas anda ravimile Mvasi müügiloa.
English: Laboratory studies comparing Mvasi with Avastin have shown that the active substance in Mvasi is highly similar to that in Avastin in terms of structure, purity and biological activity.
Estonian: Mvasit võrreldi Avastiniga laboriuuringutes, mis tõendasid, et Mvasi toimeaine sarnaneb struktuuri, puhtuse ja bioloogilise toime poolest Avastini toimeainega.
English: Mvasi is available as a concentrate that is made up into a solution for infusion (drip) into a vein.
Estonian: Mvasit turustatakse infusioonilahuse (veeni tilgutatava lahuse) kontsentraadina.
English: • breast cancer that has spread to other parts of the body;
Estonian: • Rinnavähk, mis on levinud organismis ka mujale.
English: • cancer of the ovary or associated structures (the fallopian tube that carries the egg from the ovary to the womb or the peritoneum, the membrane that lines the abdomen);
Estonian: • Vähk munasarjas, munajuhas (mille kaudu munarakk liigub munasarjast emakasse) või kõhuõõnt katvas kõhukelmes.
English: Mvasi contains the active substance bevacizumab and is a ‘biosimilar medicine'.
Estonian: Mvasi sisaldab toimeainena bevatsisumaabi ja see on bioloogiliselt sarnane ravim.
English: • cancer of the colon (large bowel) or the rectum, when it has spread to other parts of the body;
Estonian: • Käärsoole või pärasoole (jämesoole) vähk, kui see on levinud organismis ka mujale.
English: • cancer of the cervix (the neck of the womb) that has persisted or come back after treatment, or spread to other parts of the body.
Estonian: • Emakakaelavähk, mis ei allu ravile või on pärast ravi taastunud või mis on levinud organismis ka mujale.
English: Mvasi can be used in non-small cell lung cancer unless it orginates in cells of a particular type (called squamous cells);
Estonian: Mvasit tohib mitteväikerakk-kopsuvähi raviks kasutada üksnes siis, kui see ei ole lamerakulise histoloogiaga.
English: • cancer of the kidney (renal cell carcinoma) that is advanced or has spread elsewhere;
Estonian: • Neeruvähk (neerurakuline kartsinoom), mis on kaugelearenenud või levinud organismis ka mujale.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Tivicay on 16 January 2014.
Estonian: Euroopa Komisjon andis Tivicay müügiloa, mis kehtib kogu Euroopa Liidus, 16. jaanuaril 2014.
English: Tivicay is available as tablets (10, 25 and 50 mg).
Estonian: Tivicayd turustatakse tablettidena (10, 25 ja 50 mg).
English: What measures are being taken to ensure the safe and effective use of Tivicay?
Estonian: Mis meetmed võetakse, et tagada Tivicay ohutu ja efektiivne kasutamine?
English: The full EPAR and risk management plan summary for Tivicay can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Tivicay kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Tivicay dolutegravir
Estonian: Tivicay dolutegraviir
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Tivicay's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Tivicay kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Other information about Tivicay
Estonian: Muu teave Tivicay kohta
English: Tivicay does not cure HIV infection or AIDS, but it may hold off damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: Tivicay ei ravi HIV-infektsiooni ega AIDSi välja, kuid võib immuunsüsteemi kahjustumist ning AIDSiga seotud infektsioonide ja haiguste tekkimist edasi lükata.
English: It is used together with other medicines to treat adults and children from 6 years of age who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Seda kasutatakse koos teiste ravimitega täiskasvanute ja üle 6-aastaste laste raviks, kellel on inimese 1. tüüpi immuunpuudulikkuse viiruse (HIV-1) nakkus, mis põhjustab omandatud immuunpuudulikkuse sündroomi (AIDSi).
English: This is an antiviral medicine that blocks an enzyme called integrase that is needed by the HIV virus to make new copies of itself in the body.
Estonian: See on viirusvastane ravim, mis blokeerib ensüümi integraas, mida HI-viirus vajab viirusest uute koopiate tegemiseks organismis.
English: Tivicay was demonstrated to be effective against HIV-1 in four main studies in adults.
Estonian: Tivicay efektiivsust täiskasvanutel HIV-1 suhtes näidati neljas põhiuuringus.
English: What is Tivicay and what is it used for?
Estonian: Mis on Tivicay ja milleks seda kasutatakse?
English: The dose for children 6 to 12 years old depends on the weight of the child; for those aged 12 and over it is usually one 50-mg tablet a day.
Estonian: 6-12-aastaste laste annus sõltub lapse kehamassist; vähemalt 12-aastaste laste annus on tavaliselt üks 50 mg tablett üks kord ööpäevas.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tivicay have also been included in the summary of product characteristics and the package leaflet.
Estonian: Tivicay ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The medicine was generally well tolerated, although the CHMP noted the possible risk of infrequent but severe hypersensitivity reactions.
Estonian: Ravimit taluti üldiselt hästi, ehkki inimravimite komitee märkis harvaesinevate, ent raskete ülitundlikkusreaktsioonide võimalikku riski.
English: The most common side effects with Tivicay (which may affect more than 1 in 10 people) are nausea (feeling sick), diarrhoea, and headache.
Estonian: Tivicay kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on iiveldus, kõhulahtisus ja peavalu.
English: Why is Tivicay approved?
Estonian: Miks Tivicay heaks kiideti?
English: The company subsequently presented available results in 23 children from 6 to less than 12 years of age, who were given doses of Tivicay based on their body weight.
Estonian: Ettevõte esitas seejärel olemasolevad tulemused 23 lapsel vanuses 6-12 aastat, kellele manustati Tivicay annuseid vastavalt nende kehamassile.
English: This is a summary of the European public assessment report (EPAR) for Tivicay.
Estonian: See on ravimi Tivicay Euroopa avaliku hindamisaruande kokkuvõte.
English: The results indicated that similar levels of the medicine were produced in children to those seen in adults and adolescents, which should result in similar effectiveness.
Estonian: Tulemused näitasid sarnast ravimisisaldust nii lastel kui täiskasvanutel ja noorukitel, mis peaks viima sarnase efektiivsuseni.
English: Supportive data from an ongoing study in children and adolescents indicated that adolescents could be given the adult dose of Tivicay.
Estonian: Toetavad andmed käimasolevatest uuringutest lastel ja noorukitel näitasid, et noorukitele saab manustada Tivicay täiskasvanute annuse.
English: More serious adverse effects that have been reported include an uncommon but severe hypersensitivity (allergic) reaction with rash and possible effects on the liver.
Estonian: Raskemad teatatud kõrvalnähud on harvaesinev, ent raske ülitundlikkusreaktsioon (allergiline reaktsioon) koos lööbe ja võimaliku maksakahjustusega.
English: Two studies involved patients who had not previously been treated for HIV:
Estonian: Kahes uuringus osalesid patsiendid, kes ei olnud varem HIV-infektsiooni ravi saanud.
English: Patients were treated with a combination of HIV medicines that included either Tivicay or raltegravir.
Estonian: Patsiente raviti HIV-ravimite kombinatsiooniga, mis sisaldas Tivicayd või raltegraviiri.
English: The Committee concluded that the medicine had demonstrated its effectiveness in both untreated and previously treated patients, including those with resistance to integrase inhibitors.
Estonian: Inimravimite komitee järeldas, et ravimi efektiivsus on tõendatud nii varem ravitud kui ka ravimata patsientidel, sealhulgas integraasiinhibiitorite suhtes resistentsetel patsientidel.
English: • The first of these involved 715 patients whose previous treatment had not included an integrase inhibitor and whose infection was therefore not expected to be resistant to this class of medicines.
Estonian: • Ühes uuringus osales 715 patsienti, kelle varasem raviskeem ei sisaldanud integraasiinhibiitorit ja kelle infektsioon ei olnud seetõttu eeldatavalt resistentne selle ravimirühma suhtes.
English: The main measure of effectiveness in all the studies was the response rate, which was the proportion of patients with a reduction of the levels of virus (viral load) in the blood to fewer than 50 copies of HIV-1 RNA per ml.
Estonian: Efektiivsuse põhinäitaja kõigis uuringutes oli üldine ravivastus, mis näitab patsientide osakaalu, kelle vere HIV-sisaldus (viiruskoormus) vähenes alla 50 HIV-1 RNA koopia/ml.
English: In addition, the dose of Tivicay may need to be adjusted if certain medicines are taken at the same time.
Estonian: Peale selle tuleb Tivicay annust kohandada, kui seda kasutatakse koos teatud ravimitega.
English: Tivicay must not be given together with dofetilide, a medicine for disturbances of heart rhythm, as it may cause serious side effects.
Estonian: Tivicayd ei tohi kasutada koos dofetiliidiga (südame rütmihäirete ravim), sest see võib põhjustada raskeid kõrvalnähte.
English: Although Tivicay can normally be taken with or without food, patients whose virus is resistant to this class of medicines should take Tivicay with food as it helps the medicine to get absorbed.
Estonian: Kuigi Tivicayd võib võtta koos toiduga või ilma, peavad selle ravimirühma suhtes resistentse viirusega patsiendid võtma Tivicayd koos toiduga, sest see aitab ravimil paremini imenduda.
English: The adult dose depends on whether the infection is known or suspected to be resistant to medicines of the class to which Tivicay belongs (integrase inhibitors).
Estonian: Täiskasvanutel kasutatav annus sõltub sellest, kas infektsiooni põhjustav viirus on teadaolevalt või arvatavalt resistentne ravimirühma suhtes, kuhu kuulub ka Tivicay (integraasiinhibiitorid).
English: What are the risks associated with Tivicay?
Estonian: Mis riskid Tivicayga kaasnevad?
English: Two other studies looked at the effectiveness of Tivicay in patients whose previous HIV treatment had stopped working:
Estonian: Kahes ülejäänud uuringus hinnati Tivicay efektiivsust patsientidel, kelle varasem HIV-ravi oli muutunud ebaefektiivseks.
English: Tivicay is an antiviral medicine containing the active substance dolutegravir.
Estonian: Tivicay on viiruseravim, mis sisaldab toimeainena dolutegraviiri.
English: For more information about treatment with Tivicay, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Tivicayga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Tivicay can only be obtained with a prescription and should be prescribed by a doctor who is experienced in managing HIV infection.
Estonian: Tivicay on retseptiravim, mida tohib määrata ainult HIV-infektsiooni ravis kogenud arst.
English: • The second study in previously treated patients involved 183 patients with infection resistant to previous treatment that had involved an integrase inhibitor (i.e. their infection was resistant to several classes of medicine, including previous integrase inhibitors): adding Tivicay twice daily to other treatment resulted in a response rate of 69% after 24 weeks of therapy.
Estonian: • Teises uuringus osales 183 varem ravitud patsienti, kelle varasem raviskeem sisaldas integraasiinhibiitorit ja kelle nakkus oli varasemale ravile resistentne (st nende nakkus oli resistentne paljude ravimirühmade, sealhulgas varasemate integraasiinhibiitorite suhtes): Tivicay lisamisel kaks korda ööpäevas muule raviskeemile tekitas ravivastuse 69% pärast 24 ravinädalat.
English: • The second study involved 833 patients given either a combination of Tivicay with two NRTIs or a different three-drug combination (Atripla) that did not include an integrase inhibitor.
Estonian: • Teises uuringus osales 833 patsienti, kellele manustati Tivicayd koos kahe NRTIga või kolmest ravimist koosnevat kombinatsiooni (Atripla), mis ei sisaldanud integraasiinhibiitorit.
English: It is not intended to provide practical advice on how to use Tivicay.
Estonian: Hindamisaruandes ei anta Tivicay kasutamise praktilisi nõuandeid.
English: The active substance in Tivicay, dolutegravir, is an integrase inhibitor.
Estonian: Tivicay toimeaine dolutegraviir on integraasiinhibiitor.
English: For practical information about using Tivicay, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Tivicay kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: How does Tivicay work?
Estonian: Kuidas Tivicay toimib?
English: How is Tivicay used?
Estonian: Kuidas Tivicayd kasutatakse?
English: When it is given with other medicines, Tivicay helps to prevent the spread of HIV and keep the amount of the virus in the blood at a low level.
Estonian: Koos teiste ravimitega manustatav Tivicay vähendab HIVi kogust veres ja hoiab selle sisalduse väikese.
English: For the full list of all side effects reported with Tivicay, see the package leaflet.
Estonian: Tivicay kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What benefits of Tivicay have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Tivicay kasulikkus?
English: • In patients whose virus is not resistant to integrase inhibitors, the usual dose is one 50-mg tablet a day; however, when given with certain medicines that decrease the effectiveness of Tivicay the dose is increased to one 50 mg tablet twice a day.
Estonian: • Integraasiinhibiitorite suhtes mitte resistentse viirusega patsientide tavaannus on üks 50 mg tablett üks kord ööpäevas, aga manustamisel teatud, Tivicay efektiivsust vähendavate ravimitega,
English: The response rate at 48 weeks was 88% (364 of 414 patients) in those given Tivicay-based treatment compared with 81% (338 of 419 patients) in those given Atripla.
Estonian: Ravivastus 48. nädalal oli Tivicayd sisaldanud raviskeemi saanud patsientidel 88% (364 patsienti 414st) ja Atripla kombinatsiooni saanud patsientidel 81% (338 patsienti 419st).
English: Response rate at 48 weeks was 71% in patients given treatment based on Tivicay, and 64% in those given treatment based on raltegravir.
Estonian: Ravivastus 48. nädalal oli Tivicayd sisaldanud raviskeemi saanud patsientidel 71% ja raltegraviiri saanud patsientidel 64%.
English: • The dose is one 50-mg tablet twice a day in patients whose virus is known or suspected to be resistant to integrase inhibitors; in these patients, giving Tivicay with medicines that decrease its effectiveness should be avoided.
Estonian: 50 mg tablett kaks korda ööpäevas; nendel patsientidel tuleb vältida Tivicay manustamist ravimitega, mis vähendavad selle efektiivsust.
English: • In the first of these, involving 822 patients, Tivicay once daily was compared with raltegravir (another integrase inhibitor), both given in combination with two other HIV medicines of a different class (known as nucleoside reverse transcriptase inhibitors or NRTIs): 88% (361 of 411 patients) given Tivicay and 85% (351 of 411) given raltegravir responded after 48 weeks of treatment.
Estonian: • Ühes uuringus, milles osales 822 patsienti, võrreldi üks kord ööpäevas manustatud Tivicayd raltegraviiriga (samuti integraasiinhibiitor), kusjuures mõlemat kasutati kombinatsioonis kahe muusse ravimirühma kuuluva HIV-ravimiga (NRTId; nukleosiidi pöördtranskriptaasi inhibiitorid).
English: EU/1/15/1062/001 RAVICTI
Estonian: EU/1/15/1062/001
English: 1 bottle + 1 cap adapter
Estonian: 1 pudel + 1 korgi adapter
English: Oral liquid Oral or gastroenteral use bottle (glass) 25 ml
Estonian: Suukaudne või gastrointestinaalne pudel (klaas) 25 ml
English: EU (MA) Number (Invented) name
Estonian: (Väljamõeldud) nimetus
English: Strength Pharmaceuti cal Form
Estonian: Tugevus Ravimvorm Manustamistee Sisepakendi iseloomustus
English: Pack size
Estonian: RAVICTI
English: Route of Administration
Estonian: Suukaudne vedelik
English: Other medicines and Zyllt
Estonian: Muud ravimid ja Zyllt
English: Date of first authorisation: 28/9/2009 Date of latest renewal: 14 May 2014
Estonian: Müügiloa esmase väljastamise kuupäev: 28 september 2009 Müügiloa viimase uuendamise kuupäev: 14 mai 2014
English: Zyllt with food and drink Zyllt may be taken with or without food.
Estonian: Zyylt koos toidu ja joogiga Zyllt'it võib võtta koos toiduga või ilma.
English: Some other medicines may influence the use of Zyllt or vice versa.
Estonian: Mõned teised ravimid võivad mõjutada Zyllt´i toimet ja vastupidi.
English: • if you have had an allergy or reaction to any medicine used to treat your disease.
Estonian: - kui teil on varasemalt esinenud allergia või reaktsioon teie haiguse raviks kasutatud mis tahes ravimi suhtes.
English: You should take Zyllt for as long as your doctor continues to prescribe it.
Estonian: Zyllt´i tuleb võtta nii kaua, kui arst teile seda välja kirjutab.
English: • If you are allergic to clopidogrel or any of the other ingredients of this medicine (listed in section 6).
Estonian: - kui olete klopidogreeli või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline;
English: Cellulose, microcrystalline Pregelatinised maize starch Macrogol 6000
Estonian: Mikrokristalliline tselluloos Eelželatiniseeritud maisitärklis Makrogool 6000
English: • If you suffer from severe liver disease.
Estonian: - kui te põete rasket maksahaigust.
English: As a precautionary measure, breast-feeding should not be continued during treatment with Zyllt.
Estonian: Ettevaatusabinõuna ei tohi ravi ajal Zyllt´iga rinnaga toitmist jätkata.
English: 7 film-coated tablets: EU/1/09/553/001 14 film-coated tablets: EU/1/09/553/002 28 film-coated tablets: EU/1/09/553/003 30 film-coated tablets: EU/1/09/553/004 50 film-coated tablets: EU/1/09/553/005 56 film-coated tablets: EU/1/09/553/006 60 film-coated tablets: EU/1/09/553/007 84 film-coated tablets: EU/1/09/553/008 90 film-coated tablets: EU/1/09/553/009 100 film-coated tablets: EU/1/09/553/010
Estonian: 7 tabletti: EU/1/09/553/001 14 tabletti: EU/1/09/553/002 28 tabletti: EU/1/09/553/003 30 tabletti: EU/1/09/553/004 50 tabletti: EU/1/09/553/005 56 tabletti: EU/1/09/553/006 60 tabletti: EU/1/09/553/007 84 tabletti: EU/1/09/553/008 90 tabletti: EU/1/09/553/009 100 tabletti: EU/1/09/553/010
English: What Zyllt is and what it is used for
Estonian: Mis ravim on Zyllt ja milleks seda kasutatakse
English: Równoległa 5, 02-235 Warszawa, Poland KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Croatia
Estonian: Równoległa 5, 02-235 Warszawa, Poola KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Horvaatia
English: Your doctor should have prescribed Zyllt plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding.
Estonian: Teie arst peab olema teile määranud Zyllt'i koos atseüülsalitsüülhappega, kui te ei saa võtta suukaudseid antikoagulante ning teil ei ole suure verejooksu ohtu.
English: Film coating Hypromellose (E464) Titanium dioxide (E171) Red iron oxide (E172) Talc
Estonian: Hüpromelloos (E464) Titaandioksiid (E171) Punane raudoksiid (E172) Talk
English: Then, the recommended dose is one 75 mg tablet of Zyllt per day as described above.
Estonian: Seejärel on soovitatav annus üks 75 mg Zyllt´i tablett ööpäevas vastavalt ülevalpool kirjeldatule.
English: Driving and using machines Zyllt is unlikely to affect your ability to drive or to use machines.
Estonian: Autojuhtimine ja masinatega töötamine Zyllt ei tohiks avaldada mõju teie autojuhtimise või masinate käsitsemise võimele.
English: Excipients with known effect: Each film-coated tablet contains 108.125 mg lactose.
Estonian: Teadaolevat toimet omavad abiained: Üks õhukese polümeerikattega tablett sisaldab 108,125 mg laktoosi.
English: Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Estonian: Harvaesineva päriliku galaktoositalumatuse, täieliku laktaasipuudulikkuse või glükoos-galaktoosi malabsorptsiooniga patsiendid ei tohi seda ravimit võtta.
English: Warnings and precautions If any of the situations mentioned below apply to you, you should tell your doctor before taking Zyllt:
Estonian: Hoiatused ja ettevaatusabinõud Kui teil esineb mõni allpool nimetatud seisund, peate sellest enne Zyllt´i kasutamist arstile rääkima:
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
Estonian: Täpne informatsioon selle ravimi kohta on kättesaadav Euroopa Ravimiameti kodulehelhttp://www.ema.europa.eu/.
English: If you experience prolonged bleeding when taking Zyllt If you cut or injure yourself, it may take longer than usual for bleeding to stop.
Estonian: Kui märkate Zyllt´i võtmise ajal veritsusaja pikenemist Kui te endale sisse lõikate või end vigastate, võib veritsuse peatumine võtta pisut rohkem aega kui tavaliselt.